Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass (GLP-1)
The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism.
The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims.
- To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp.
- To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals.
- To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.
Drug: exendin -(9-39)
|Study Design:||Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: Single Blind (Subject)
|Official Title:||The Role of Glucagon Like Peptide-1 in Glucose Metabolism and Weight Loss Following Gastric Bypass Surgery|
- The investigator measure glucose, islet and GI hormonal levels in response to meal ingestion as a composite measure and the percentage of contribution of GLP-1 contribution to postprandial insulin levels will also be calculated [ Time Frame: up to 1 year (10 sessions) ] [ Designated as safety issue: No ]
|Study Start Date:||November 2005|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Experimental: hyperglycemic clamp-Meal tolerance test
these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls
hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion
Experimental: Labeled meal tolerance test
The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test
Drug: exendin -(9-39)
2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01803451
|Contact: Carol A Colegate, RPhfirstname.lastname@example.org|
|Contact: Marzieh Salehi, MDemail@example.com|
|United States, Ohio|
|The University of Cincinnati||Recruiting|
|Cincinnati, Ohio, United States, 45219|
|Contact: Carol A Colegate, RPh 513-558-0201 firstname.lastname@example.org|
|Principal Investigator: Marzieh Salehi, MD|
|Principal Investigator:||Marzieh Salehi, MD||University of Cincinnati|